The European Commission's Approval of Adcetris: A Causal Analysis of Advancements in Hodgkin's Lymphoma Treatment

The European Commission's (EC) recent approval of Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) in combination with the chemotherapy regimen ECADD for adults with newly diagnosed Stage IIb Hodgkin's lymphoma (HL) with risk factors or Stage III/IV marks a significant milestone in the treatment of this disease.